Study to Evaluate the Efficacy, Safety and Tolerability of an Oral Aripiprazole/Escitalopram Combination Therapy in Participants With Major Depressive Disorder (MDD)
Public ClinicalTrials.gov record NCT01111565. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Multicenter, Randomized, Double-blind Study to Evaluate the Efficacy, Safety and Tolerability of an Oral Aripiprazole/Escitalopram Combination Therapy in Patients With Major Depressive Disorder
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This will be a multicenter, randomized, double-blind study designed to assess the efficacy, safety and tolerability of an oral Aripiprazole/Escitalopram combination therapy in participants with MDD who have demonstrated an incomplete response to a prospective trial of Escitalopram, and report a treatment history for the current MDD episode of an inadequate response to at least one and no more than three adequate trials of an approved antidepressant other than Escitalopram. An inadequate response is defined as less than a 50% reduction in depressive symptom severity as assessed by the participant's self-report on the Massachusetts General Hospital Antidepressant Treatment Response Questionnaire (ATRQ) and evaluated by the investigator as part of the participant's medical and psychiatric history. An adequate trial is defined as an antidepressant treatment for at least 6 weeks duration (or at least 3 weeks for combination treatments) at an approved dose as specified in the ATRQ.
Study identification
- NCT ID
- NCT01111565
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 137 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years to 65 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Oct 3, 2010
- Primary completion
- Aug 31, 2011
- Completion
- Aug 31, 2011
- Last update posted
- Dec 20, 2021
2010 – 2011
United States locations
- U.S. sites
- 15
- U.S. states
- 11
- U.S. cities
- 15
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Not listed | Tucson | Arizona | 85710 | — |
| Not listed | Chino | California | 91710 | — |
| Not listed | Riverside | California | 92506 | — |
| Not listed | Torrance | California | 90502 | — |
| Not listed | Hamden | Connecticut | 06518 | — |
| Not listed | Marietta | Georgia | 30060 | — |
| Not listed | Belmont | Massachusetts | 02478 | — |
| Not listed | Weymouth | Massachusetts | 02190 | — |
| Not listed | Saint Charles | Missouri | 63301 | — |
| Not listed | St Louis | Missouri | 63141 | — |
| Not listed | Brooklyn | New York | 11235 | — |
| Not listed | Garfield Heights | Ohio | 44125 | — |
| Not listed | Philadelphia | Pennsylvania | 19107 | — |
| Not listed | East Providence | Rhode Island | 02914 | — |
| Not listed | Kirkland | Washington | 98033 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 38 non-U.S. sites.
Recently updated Major Depressive Disorder (MDD) trials
Other public records listing Major Depressive Disorder (MDD). Sorted by last update posted; newest first. Not a recommendation.
- NCT07792252: REWIRE: Real-world Engagement With Interventional and Rejoyn Effectiveness Not yet recruiting
- NCT07610473: A Study to Evaluate the Effectiveness of DT-101 as an Adjunctive Treatment in Patients With Depression Recruiting
- NCT07734701: Pregnenolone Treatment for Alcohol Use Disorder and Major Depressive Disorder Not yet recruiting
- NCT07139834: Pattern Separation in Major Depressive Disorder Recruiting
- NCT07685964: Pregnenolone for Cannabis Use Disorder and Depression Not yet recruiting
- NCT07621237: A Study to Evaluate TNX-102 SL Monotherapy Versus Placebo in Participants With Major Depressive Disorder (MDD) Recruiting
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01111565, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Dec 20, 2021 · Synced Sep 4, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT01111565 live on ClinicalTrials.gov.